Speaker Profile
M.D., CEO, Heteron BIotechnologies,
Biography
Anastasia Rigas leads Heteron Biotechnologies in developing aclinical-stage breath diagnostics platform that leverages advanced machinelearning to transform complex breath profilescontaining thousands of gasesand VOCsinto precise, multi-indication diagnostics. Under her leadership,Heterons multidisciplinary team has applied and rigorously tested variousmodels on proprietary datasets, achieving exceptionally high classificationaccuracy. This builds on prior peer-reviewed expertise now integratedin-house, positioning the platform to detect H. pylori for gastric cancerprevention, stratify metabolic syndrome risk, and enable future hepatic andperformance health applications. The technology is advancing under FDA CDRHoversight with pivotal trials in preparation and secured by global PCTfilings covering hardware, software, and disease-specific biomarkers.Passionate about shifting healthcare from reactive intervention toAI-driven prevention, Anastasia coordinates regulatory strategy,multi-center clinical design, and strategic partnerships to establishbreath-based machine learning diagnostics as a new paradigm in accessibleprecision medicine
Talk
AI Breath Diagnostics for Early Disease Detection
Heterons multi-gas breath platform integrates proprietary machine learningto classify complex VOC profiles, enabling accurate point-of-care diagnosisof H. pylori, Celiac and metabolic syndrome. Advancing under FDA CDRHoversight with global PCT protection, it delivers scalable, reimbursableAI-driven diagnostics that identify earlier-stage disease, improvingoutcomes through timely, informed clinical intervention.
AI and Data Sciences Showcase:
Heteron BIotechnologies,
Heteron is a clinical-stage diagnostics company advancing a multi-gasbreath analysis platform that uses proprietary machine learning to deliverprecise, multi-indication detection from complex breath samples. Thetechnology targets scalable, reimbursable screening for gastric cancerprevention, metabolic syndrome, Celiac Disease and broader preventivecare.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
